Global Companion Diagnostic Tests in Oncology Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

Description

List of Tables

The global demand for Companion Diagnostic Tests in Oncology Market is presumed to reach the market size of nearly USD 13.99 Billion by 2032 from USD 5.89 Billion in 2023 with a CAGR of 10.09% under the study period 2024 - 2032.

Companion diagnostic tests in oncology are designed to identify specific biomarkers or molecular targets associated with a patient's cancer diagnosis or prognosis. These tests are used with targeted cancer therapies to personalize treatment decisions, predict treatment response, and monitor disease progression. These tests analyze biological samples such as tissue biopsies, blood samples, or circulating tumor DNA to detect genetic mutations, gene amplifications, protein expression levels, or other molecular alterations indicative of cancer subtype, stage, or treatment response. By providing actionable information about a patient's tumor biology, companion diagnostic tests enable oncologists to tailor treatment strategies, optimize therapy selection, and improve patient outcomes in precision oncology practice.

MARKET DYNAMICS

The spurring prevalence of cancer worldwide, coupled with advancements in molecular biology and genomics, is driving the development and adoption of companion diagnostic tests for personalized cancer treatment. Additionally, the escalating emphasis on precision medicine and value-based healthcare drives demand for companion diagnostic tests that help optimize treatment outcomes, minimize adverse effects, and reduce healthcare costs. Moreover, regulatory agencies' initiatives to streamline drug approval processes and encourage the development of targeted therapies are driving investment in companion diagnostic test development and commercialization. Furthermore, collaborations and partnerships between pharmaceutical companies, diagnostic laboratories, and research institutions drive innovation and accelerate the development of companion diagnostic tests for emerging biomarkers and therapeutic targets. Additionally, the growing adoption of liquid biopsy and next-generation sequencing (NGS) technologies is expanding the scope and capabilities of companion diagnostic tests, enabling non-invasive and comprehensive profiling of tumors for precision oncology applications. However, the evolving regulatory landscape and reimbursement challenges may challenge the companion diagnostic tests in oncology market growth in the coming years.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of companion diagnostic tests in oncology. The growth and trends of companion diagnostic tests in oncology industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the companion diagnostic tests in oncology market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Detection Technique

Protein Detection (Immunohistochemistry)
DNA Detection (Polymerase Chain Reaction (Pcr), Next-Generation Sequencing (Ngs), In Situ Hybridization)
Others

By Biomarker

EGFR
KRAS
HER2
BRAF V600E
Others

By Cancer Type

Breast Cancer
Lung Cancer
Colorectal Cancer
Liver Cancer
Melanoma
Others

By End-User

Hospitals
Specialty Clinics
Diagnostic Labs
Others

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Companion Diagnostic Tests in Oncology market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Companion Diagnostic Tests in Oncology market include Abbott, F. Hoffmann-LA Roche AG, Genomic Health, Inc., Qiagen, Agilent Technologies, Inc., Agendia N.V., bioMerieux SA, Illumina, Inc., Siemens Healthineers, Thermo Fisher Scientific Inc., BioGenex. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

Product Code: VMR112114403

1. PREFACE

1.1. Report Description
- 1.1.1 Objective
- 1.1.2 Target Audience
- 1.1.3 Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1 Market Research Process
- 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3. COMPANION DIAGNOSTIC TESTS IN ONCOLOGY - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Detection Technique
- 3.7.2 Market Attractiveness Analysis By Biomarker
- 3.7.3 Market Attractiveness Analysis By Cancer Type
- 3.7.4 Market Attractiveness Analysis By End-user
- 3.7.5 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1 List of Raw Materials
- 4.2.2 Raw Material Manufactures List
- 4.2.3 Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1 Direct Marketing
- 4.4.2 Indirect Marketing
- 4.4.3 Marketing Channel Development Trend

5. GLOBAL COMPANION DIAGNOSTIC TESTS IN ONCOLOGY MARKET ANALYSIS BY DETECTION TECHNIQUE

5.1. Overview By Detection Technique
5.2. Historical and Forecast Data
5.3. Analysis By Detection Technique
5.4. Protein Detection (Immunohistochemistry) Historic and Forecast Sales By Regions
5.5. DNA Detection (Polymerase Chain Reaction (PCR), Next-generation Sequencing (NGS), In Situ Hybridization) Historic and Forecast Sales By Regions
5.6. Others Historic and Forecast Sales By Regions

6. GLOBAL COMPANION DIAGNOSTIC TESTS IN ONCOLOGY MARKET ANALYSIS BY BIOMARKER

6.1. Overview By Biomarker
6.2. Historical and Forecast Data
6.3. Analysis By Biomarker
6.4. EGFR Historic and Forecast Sales By Regions
6.5. KRAS Historic and Forecast Sales By Regions
6.6. HER2 Historic and Forecast Sales By Regions
6.7. BRAF V600E Historic and Forecast Sales By Regions
6.8. Others Historic and Forecast Sales By Regions

7. GLOBAL COMPANION DIAGNOSTIC TESTS IN ONCOLOGY MARKET ANALYSIS BY CANCER TYPE

7.1. Overview By Cancer Type
7.2. Historical and Forecast Data
7.3. Analysis By Cancer Type
7.4. Breast Cancer Historic and Forecast Sales By Regions
7.5. Lung Cancer Historic and Forecast Sales By Regions
7.6. Colorectal Cancer Historic and Forecast Sales By Regions
7.7. Liver Cancer Historic and Forecast Sales By Regions
7.8. Melanoma Historic and Forecast Sales By Regions
7.9. Others Historic and Forecast Sales By Regions

8. GLOBAL COMPANION DIAGNOSTIC TESTS IN ONCOLOGY MARKET ANALYSIS BY END-USER

8.1. Overview By End-user
8.2. Historical and Forecast Data
8.3. Analysis By End-user
8.4. Hospitals Historic and Forecast Sales By Regions
8.5. Specialty Clinics Historic and Forecast Sales By Regions
8.6. Diagnostic Labs Historic and Forecast Sales By Regions
8.7. Others Historic and Forecast Sales By Regions

9. GLOBAL COMPANION DIAGNOSTIC TESTS IN ONCOLOGY MARKET ANALYSIS BY GEOGRAPHY

9.1. Regional Outlook
9.2. Introduction
9.3. North America Sales Analysis
- 9.3.1 Overview, Historic and Forecast Data Sales Analysis
- 9.3.2 North America By Segment Sales Analysis
- 9.3.3 North America By Country Sales Analysis
- 9.3.4 United States Sales Analysis
- 9.3.5 Canada Sales Analysis
- 9.3.6 Mexico Sales Analysis
9.4. Europe Sales Analysis
- 9.4.1 Overview, Historic and Forecast Data Sales Analysis
- 9.4.2 Europe By Segment Sales Analysis
- 9.4.3 Europe By Country Sales Analysis
- 9.4.4 United Kingdom Sales Analysis
- 9.4.5 France Sales Analysis
- 9.4.6 Germany Sales Analysis
- 9.4.7 Italy Sales Analysis
- 9.4.8 Russia Sales Analysis
- 9.4.9 Rest Of Europe Sales Analysis
9.5. Asia Pacific Sales Analysis
- 9.5.1 Overview, Historic and Forecast Data Sales Analysis
- 9.5.2 Asia Pacific By Segment Sales Analysis
- 9.5.3 Asia Pacific By Country Sales Analysis
- 9.5.4 China Sales Analysis
- 9.5.5 India Sales Analysis
- 9.5.6 Japan Sales Analysis
- 9.5.7 South Korea Sales Analysis
- 9.5.8 Australia Sales Analysis
- 9.5.9 South East Asia Sales Analysis
- 9.5.10 Rest Of Asia Pacific Sales Analysis
9.6. Latin America Sales Analysis
- 9.6.1 Overview, Historic and Forecast Data Sales Analysis
- 9.6.2 Latin America By Segment Sales Analysis
- 9.6.3 Latin America By Country Sales Analysis
- 9.6.4 Brazil Sales Analysis
- 9.6.5 Argentina Sales Analysis
- 9.6.6 Peru Sales Analysis
- 9.6.7 Chile Sales Analysis
- 9.6.8 Rest of Latin America Sales Analysis
9.7. Middle East & Africa Sales Analysis
- 9.7.1 Overview, Historic and Forecast Data Sales Analysis
- 9.7.2 Middle East & Africa By Segment Sales Analysis
- 9.7.3 Middle East & Africa By Country Sales Analysis
- 9.7.4 Saudi Arabia Sales Analysis
- 9.7.5 UAE Sales Analysis
- 9.7.6 Israel Sales Analysis
- 9.7.7 South Africa Sales Analysis
- 9.7.8 Rest Of Middle East And Africa Sales Analysis

10. COMPETITIVE LANDSCAPE OF THE COMPANION DIAGNOSTIC TESTS IN ONCOLOGY COMPANIES

10.1. Companion Diagnostic Tests in Oncology Market Competition
10.2. Partnership/Collaboration/Agreement
10.3. Merger And Acquisitions
10.4. New Product Launch
10.5. Other Developments

11. COMPANY PROFILES OF COMPANION DIAGNOSTIC TESTS IN ONCOLOGY INDUSTRY

11.1. Top Companies Market Share Analysis
11.2. Market Concentration Rate
11.3. Abbott
- 11.3.1 Company Overview
- 11.3.2 Company Revenue
- 11.3.3 Products
- 11.3.4 Recent Developments
11.4. F. Hoffmann-LA Roche AG
- 11.4.1 Company Overview
- 11.4.2 Company Revenue
- 11.4.3 Products
- 11.4.4 Recent Developments
11.5. Genomic Health Inc.
- 11.5.1 Company Overview
- 11.5.2 Company Revenue
- 11.5.3 Products
- 11.5.4 Recent Developments
11.6. QIAGEN
- 11.6.1 Company Overview
- 11.6.2 Company Revenue
- 11.6.3 Products
- 11.6.4 Recent Developments
11.7. Agilent Technologies Inc.
- 11.7.1 Company Overview
- 11.7.2 Company Revenue
- 11.7.3 Products
- 11.7.4 Recent Developments
11.8. Agendia N.V.
- 11.8.1 Company Overview
- 11.8.2 Company Revenue
- 11.8.3 Products
- 11.8.4 Recent Developments
11.9. BioMeRieux SA
- 11.9.1 Company Overview
- 11.9.2 Company Revenue
- 11.9.3 Products
- 11.9.4 Recent Developments
11.10. Illumina Inc.
- 11.10.1 Company Overview
- 11.10.2 Company Revenue
- 11.10.3 Products
- 11.10.4 Recent Developments
11.11. Siemens Healthineers
- 11.11.1 Company Overview
- 11.11.2 Company Revenue
- 11.11.3 Products
- 11.11.4 Recent Developments
11.12. Thermo Fisher Scientific Inc.
- 11.12.1 Company Overview
- 11.12.2 Company Revenue
- 11.12.3 Products
- 11.12.4 Recent Developments
11.13. BioGenex.
- 11.13.1 Company Overview
- 11.13.2 Company Revenue
- 11.13.3 Products
- 11.13.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies